

Author Index

- Abdollahi M
3(1), 113–117
3(1), 119–123
3(3), 413–419
- Afshari M
3(1), 119–123
- Agnese V
3(3), 401–407
- Ahmed M
3(1), 1–3
- Aidietis A
3(1), 125–138
- Akman A
3(1), 139–151
- Alpsoy E
3(1), 139–151
- Amsden GW 3
(3), 359–365
- Antoniou KM
3(1), 163–174
- Arora S
3(3), 409–412
- Astanehi–Asghari F
3(1), 119–123
- Augello C
3(3), 401–407
- Badalamenti Ge
3(3), 401–407
- Baiaty A
3(1), 113–117
- Barnett AH
3(3), 339–348
- Barua JM
3(3), 397–400
- Bazan V
3(3), 401–407
- Beaulieu J
3(1), 69–78
- Beck M
3(1), 9–17
- Bellary S
3(3), 339–348
- Born L
3(1), 153–162
- Bouros D
3(1), 163–174
- Brook NR
3(3), 421–430
- Bubb C
3(3), 409–412
- Cackett P
3(3), 401–402
- Calò V
3(3), 401–407
- Cameron JR
3(3), 401–402
- Cascio S
3(3), 401–407
- Clarke A
3(3), 349–357
- Colquhoun AJ
3(3), 421–430
- Deshmogh M
3(3), 409–412
- DiBaise JK
3(1), 55–67
- Dieter RS
3(1), 1–3
- Dupont C
3(1), 69–78
- Eftekhari B
3(3), 413–419
- Eftekhari R
3(3), 413–419
- El–Atat F
3(3), 409–412
- Ellegard EK
3(1), 89–92
- Ellegard LH
3(1), 89–92
- Esmaily H
3(3), 413–419
- Fricano S
3(3), 401–407
- Gebbi N
3(3), 401–407
- Gebreegziabher Y
3(3), 409–412
- Geriniere L
3(3), 367–378
- Ghaffarzadeh M
3(3), 413–419
- Ghameinezhad S
3(1), 113–117
- Giordano A
3(3), 401–407
- Gliwa A
3(3), 409–412
- Gregorio V
3(3), 401–407
- Hadidi E
3(3), 413–419
- Hehmat R
3(1), 119–123
- Hosseinnezhad A
3(1), 119–123
- Hunt MA
3(1), 97–112
- Ikram S
3(1), 1–3
- Jahke K
3(1), 97–112
- Jankovic J
3(3), 349–357
- Joseph L
3(3), 409–412
- Khajavi MR
3(3), 413–419
- Kraemer DF
3(1), 97–112
- Larjani B
3(1), 119–123
- Lebert F
3(1), 93–96
- Lemieux P
3(1), 69–78
- Lip PL
3(3), 431–438
- Malekirad AA
3(1), 113–117
- Marinskis G
3(1), 125–138
- Maron L
3(1), 97–112
- McFarlane SI
3(3), 409–412
- Mellish D
3(3), 409–412
- Mellon J
3(3), 421–430
- Menon VJK
3(3), 431–438
- Miyasaka N
3(3), 379–378
- Mohammadirad A
3(1), 113–117
- Mojtahedzadeh M
3(3), 413–419
- Mojtahedi A
3(1), 119–123
- Morris B
3(3), 401–402
- Muldoon LL
3(1), 97–112
- Najafi A
3(3), 413–419
- Nanjundappa A
3(1), 1–3
- Napoli L
3(3), 401–407
- Neuwelt EA
3(1), 97–112
- Nicasio J
3(3), 409–412
- Nikfar S
3(3), 413–419
- Orbay P
3(1), 97–112
- Ormerod AD
3(3), 439–450
- Pacanowski Jr J
3(1), 1–3
- Paknejad MH
3(3), 413–419
- Phillips SD
3(1), 153–162
- Ranjbar A
3(1), 113–117
- Rajpara SM
3(3), 439–450
- Rezaie A
3(1), 119–123
- Rouini MR
3(3), 413–419
- Rundek T
3(3), 329–333
- Rusconi S
3(1), 79–88
- Russo A
3(3), 401–407
- Sahraian MA
3(3), 413–419
- Santini D
3(3), 401–407
- Schwartz J RL
3(3), 379–396
- Scoppettuolo E
3(3), 401–402
- Shatzkes J
3(3), 409–412
- Shergill IS
3(3), 397–400
- Singh J
3(3), 401–402
- Sisto PS
3(3), 401–407
- Soleimani V
3(3), 413–419
- Souquet PJ
3(3), 367–378
- Tatum M
3(3), 359–365
- Turgay A
3(1), 19–38
- Tyson RM
3(1), 97–112
- Tzouvelekis A
3(1), 163–174
- Vazquez JA
3(1), 39–54
- Vigano O
3(1), 79–88

APPENDICES

Cumulative indices for 2006

Woo PN 3(3), 439–450	Amprenavir (APV) 3(1), 79–88	Breast-secreting duct 3(3), 403–407	Corticosteroids 3(1), 139–151
Zamani MJ 3(3), 413–419	Angiotensin-converting enzyme inhibitors 3(1), 125–138	Bupropion 3(1), 19–38 3(1), 153–162	CP-358-774 3(3), 421–430
Zamani H 3(1), 113–117	Anidulafungin 3(1), 39–54	Burow's solution 3(1), 139–151	Cremophor EL 3(3), 367–378
Zinga D 3(1), 153–162	Anthracycline 3(1), 97–112	Capecitabine 3(1), 97–112	Cyclophosphamide 3(1), 97–112 3(1), 139–151
Compound Index	Antidepressants 3(1), 19–38	Carbamazepine 3(1), 39–54	Cyclosporine 3(1), 39–54 3(1), 139–151 3(3), 439–450
2,4,6-tripyridyl-5-triazine 3(1), 113–117	Anti-HIV-1 3(1), 79–88	Carbapenems 3(1), 163–174	Cylcosporin A 3(1), 139–151 3(3), 367–378
2-thiobarbituric acid 3(1), 113–117	Antiangiogenic agents 3(3), 431–438	Carboplatin 3(1), 97–112	Dapsone 3(1), 139–151
5-fluorouracil 3(1), 97–112	Antihyperglycemic therapy 3(3), 339–348	Carvedilol 3(1), 119–123	Desipramine 3(1), 19–38
^{99m} Tc-glucuheptonate 3(1), 97–112	Antihypertensives 3(1), 19–38	Caspofungin 3(1), 39–54	Dexamethasone 3(1), 39–54 3(1), 69–78
^{99m} Tc-albumin 3(1), 97–112	Antipseudomonal penicillins 3(1), 163–174	Cataplexy 3(3), 389–396	Dexedrine® (see dextroamphermine)
α-lactalbumin	Antipseudomonal quinolones 3(1), 163–174	Catapres® (see clonidine)	Dextroamphermine 3(1), 19–38
Acetylcholinesterase 3(1), 93–96	Antitumor necrosis factor-α 3(1), 139–151	Cephalosporins 3(1), 163–174	Diabetes mellitus 3(3), 329–333 3(3), 339–348
Acute brain injury 3(3), 413–419	Armodafinil 3(3), 389–396	Cetuximab 3(3), 421–430	Diclofenac 3(1), 139–151
Acute urinary retention 3(3), 421–430	Atazanavir 3(1), 79–88	Chemotherapy 3(3), 421–430	Dihydrotestosterone 3(3), 397–400
Adalimumab 3(3), 379–387 3(3), 439–450	Atomoxetine hydrochloride 3(1), 19–38	Chlorambucil 3(1), 139–151	Dithiobis-2-nitrobenzoic acid 3(1), 113–117
Adderal XR® (see psychostimulants)	Azathioprine 3(1), 139–151	Chlorhexidine 3(1), 139–151	DMP 450® (see mozenavir)
Adriamycin 3(1), 97–112	Azithromycin 3(3), 359–365	Cholinergic acetyltransferase 3(1), 93–96	Docetaxel 3(1), 97–112 3(3), 367–378
Aerodose® (see inhaled human insulin)	Azoles 3(1), 39–54	Cholinesterase inhibitors 3(1), 93–96	Doxorubicin 3(1), 97–112
AERx® (see inhaled human insulin)	Aztreonam 3(1), 163–174	Choroidal neovascularization 3(3), 431–438	Doxycycline 3(3), 359–365
AG-001859 3(1), 79–88	β-blocker 3(1), 125–138 3(1), 119–123	<i>Cinnamomum zeylanicum</i> 3(1), 113–117	Ductal fluid 3(3), 403–407
AG1478 3(3), 421–430	β-lactoglobulin 3(1), 69–78	Ciprofloxacin 3(1), 163–174	Ductal lavage 3(3), 403–407
Age-related macular degeneration 3(3), 431–438	β-lactotensin 3(1), 69–78	Cisplatin 3(1), 97–112 3(3), 367–378	Dutasteride 3(3), 397–400
AIR system (see inhaled human insulin)	Benzatin penicillin 3(1), 139–151	Citalopram 3(1), 153–162	Dx Spansule® (see psychostimulants))
AIR® (see inhaled human insulin)	Benzylamine 3(1), 139–151	Clindamycin 3(1), 163–174	Echinocardins 3(1), 39–54
Aldosterone receptor blockers 3(1), 125–138	Bilateral angle-closure glaucoma 3(3), 421–430	Clonidine 3(1), 19–38	Epidermal growth factor receptor 3(3), 421–430
Alefacept 3(3), 439–450	BILA-2185 BS 3(1), 79–88	CNS stimulants 3(3), 389–396	Erlotinib 3(3), 421–430
Alteplase 3(1), 163–174	Bovine serum albumin 3(1), 69–78	Colchicine 3(1), 139–151	Etanercept 3(1), 139–151
Aluminium acetate 3(1), 139–151	BR96-DOX 3(1), 97–112	Concerta® (see psychostimulants)	3(3), 379–387 3(3), 439–450
Amiodarone 3(1), 125–138	Breast cancer 3(3), 403–407	Coronary artery disease 3(3), 329–333	

- Etoposide
 3(1), 97–112
 Etoposide phosphate
 3(1), 97–112
 Excessive sleepiness
 3(3), 389–396
 Exubera® (see inhaled human insulin)
 First-generation HIV-1 protease inhibitors
 3(1), 79–88
 Fluoxetine
 3(1), 19–38
 3(1), 153–162
 Fluvoxamine
 3(1), 93–96
 3(1), 153–162
 Focalin® (see psychostimulants)
 Galsulfase
 3(1), 9–17
 Gemcitabine
 3(1), 97–112
 GI198745 (see Dutasteride)
 Glibenclamide
 3(3), 339–348
 Glutamine
 3(1), 55–67
 Glutathione
 3(1), 113–117
 Glycyl-leucyl-phenylalanine
 3(1), 69–78
 Guanfacine
 3(1), 19–38
 GW640385
 3(1), 79–88
 Herstatin
 3(1), 97–112
 Herstatin
 3(1), 97–112
 Hexetidinie
 3(1), 139–151
 IFN-2 α
 3(1), 139–151
 IFN-a?
 3(1), 139–151
 Imipramine
 3(1), 19–38
 Immunoglobulin
 3(1), 69–78
 Indinavir
 3(1), 79–88
 Infliximab
 3(1), 139–151
 3(3), 439–450
 3(3), 379–387
 Inhaled human insulin
 3(3), 339–348
 Insufflation
 3(3), 403–407
 Interferon
 3(1), 139–151
 Intracerebral hemorrhage
 3(3), 413–419
 Intravenous aminopenicillin
 3(1), 163–174
 Iressa® (see Gefitinib)
 Itraconazole
 3(1), 39–54
 Lactoferrin
 3(1), 69–78
 Lapatinib
 3(1), 97–112
 3(3), 421–430
 Laronidase
 3(1), 9–17
 Levamisole
 3(1), 139–151
 Levodopa
 3(3), 349–357
 Lidocaine
 3(1), 139–151
 Liposomal doxorubicin
 3(1), 97–112
 Listerine
 3(1), 139–151
 Lopinavir
 3(1), 79–88
 Lorazepam
 3(1), 153–162
 Low-density lipoprotein
 3(3), 329–333
 Luciferase
 3(1), 97–112
 Macrolides
 3(3), 359–365
 Macula
 3(3), 431–438
 Malonedialdehyde
 3(1), 113–117
 Mannitol
 3(1), 97–112
 Mepivacaine
 3(1), 139–151
 Metadate CD® (see psychostimulants)
 Metformin
 3(3), 339–348
 Methotrexate
 3(1), 97–112
 3(1), 139–151
 3(3), 379–387
 3(3), 439–450
 Methylin ER® (see psychostimulants)
 Methylphenidate
 3(1), 19–38
 Methylphenidate SR® (see psychostimulants)
 Methylprednisolone
 3(1), 139–151
 Methypatch® (see psychostimulants)
 Micafungin
 3(1), 39–54
 MicroDose
 (see inhaled human insulin)
 Microsphere formulation
 3(3), 359–365
 Modafinil
 3(3), 389–396
 Mozenavir
 3(1), 79–88
 Myocardial infarction
 3(3), 329–333
 Narcolepsy
 3(3), 389–396
 Nateglinide
 3(3), 329–333
 Nefazodone
 3(1), 153–162
 Nelfinavir
 3(1), 79–88
 Nipple
 3(3), 403–407
 Nucleoside
 3(1), 79–88
 Non-nucleoside inhibitors of reverse transcriptase
 3(1), 79–88
 Ondansetron
 3(1), 97–112
 Orabase
 3(1), 139–151
 Oral retinoids
 3(3), 439–450
 Orally disintegrating tablet
 3(3), 349–357
 Ovalbumin
 3(1), 69–78
 Oxaliplatin
 3(1), 97–112
 Oxazolone
 3(1), 69–78
 Paclitaxel
 3(1), 1–3
 3(1), 97–112
 3(3), 367–378
 Paroxetine
 3(1), 19–38
 3(1), 93–96
 3(1), 153–162
 Paxil® (see paroxetine)
 PD153035
 3(3), 421–430
 Penicillins
 3(1), 163–174
 Phenobarbital
 3(1), 153–162
 Piracetam
 3(1), 93–96
 Pioglitazone
 3(3), 329–333
 Provigil® (see modafinil)
 PL100
 3(1), 79–88
 Posaconazole
 3(1), 39–54
 Prednisolone
 3(1), 139–151
 Prednisone
 3(1), 97–112
 Psoralen
 3(3), 439–450
 Psychostimulants
 3(1), 19–38
 Quinazoline
 3(3), 421–430
 Recombinant human growth hormone
 3(1), 55–67
 Resistant-Repellent™ (see SPI-70095)
 Rifampin
 3(1), 39–54
 Ritalin LA® (see psychostimulants)
 Ritalin SR® (see psychostimulants)
 Ritalin® (see methylphenidate)
 Ritalin® (see methylphenidate)
 Ritonavir
 3(1), 79–88
 Rosiglitazone
 3(3), 339–348
 Rosuvastatin
 3(3), 329–333
 Saquinavir
 3(1), 79–88
 Second-generation cephalosporin
 3(1), 163–174
 Selective estrogen-receptor modulator
 3(3), 403–407
 Selective serotonin reuptake inhibitor
 3(3), 421–430
 Selective norepinephrine reuptake inhibitor
 3(1), 19–38
 3(1), 153–162
 Selegiline
 3(3), 349–357
 Serotonin selective re-uptake inhibitors

APPENDICES

- 3(1), 93–96
3(3), 421–430
- Sertraline
3(1), 153–162
- Several second-generation protease inhibitors
3(1), 79–88
- SGN-15
3(1), 97–112
- Silver nitrate
3(1), 139–151
- Sirolimus
3(1), 1–3
- Sodium oxybate
3(3), 389–396
- Sodium thiosulfate
3(1), 97–112
- Somatropin
3(1), 55–67
- Sotalol
3(1), 125–138
- SPI-70095
3(1), 79–88
- Spiros® (see inhaled human insulin)
- SPSS®
3(3), 409–412
- Statins
3(1), 125–138
- Strattera® (see atomoxetine hydrochloride)
- Streptodornase
3(1), 163–174
- Streptodornase-a
3(1), 163–174
- Streptokinase
3(1), 163–174
- Sucralfate
3(1), 139–151
- Superparamagnetic iron oxide nanoparticles
3(1), 97–112
- Tacrolimus
3(1), 39–54
- Tamoxifen
3(1), 19–38
3(3), 403–407
- Tarceva® (see Erlotinib)
- Taxane
3(3), 367–378
- Taxol® (see Paclitaxel)
- Taxotere
3(1), 97–112
- Technosphere® (see inhaled human insulin)
- Tenex® (see guanfacine)
- Testosterone
3(3), 397–400
- Tetracaine
3(1), 139–151
- Tetracycline
3(1), 139–151
- Tetraethoxypropane
3(1), 113–117
- Tetrahydrofuran
3(1), 79–88
- Thalidomide
3(1), 139–151
- Thrombocytopenia
3(3), 367–378
- Trastuzumab
3(3), 421–430
- Transient ischemic attack
3(3), 329–333
- Transitional cell carcinoma
3(3), 421–430
- Traumatic brain injury
3(3), 413–419
- Tricyclic antidepressants
3(3), 401–402
- Third-generation cephalosporins
3(1), 163–174
- Tipranavir
3(1), 79–88
- TMC 114
3(1), 79–88
- TMC 126
3(1), 79–88
- Tofranil® (see imipramine)
- Topoisomerase I agents
3(1), 97–112
- Topoisomerase II agents
3(1), 97–112
- Trastuzumab
3(1), 97–112
- Trazodone
3(1), 153–162
- Trazodone
3(1), 93–96
- Triamcinolone acetonide
3(1), 139–151
- Trichloroacetic acid
3(1), 113–117
- Tricyclic antidepressants
3(1), 19–38
- Tricyclics
3(1), 153–162
- Tris base
3(1), 113–117
- Tween 80
3(3), 367–378
- Tyr-gly-gly
3(1), 69–78
- Valsartan
3(3), 329–333
- Vancomycin
3(1), 163–174
- Venlafaxine
3(1), 153–162
- Venlafaxine
3(1), 19–38
- Verapamil
3(1), 125–138
- Verteporfin
3(3), 431–438
- Vincristine
3(1), 97–112
- Vinorelbine
3(1), 97–112
- Voriconazole
3(1), 39–54
- Welbutrin® (see bupropion)
- ZD1839
3(3), 421–430
- Zydis® (see Selegiline)